Natural products targeting cancer stem cells: a promising therapeutic approach

Abstract

Cancer remains the second leading cause of death globally, posing an ongoing threat to public health. A hallmark of cancer cells is their capacity to invade adjacent tissues and evolve into malignant forms, often resulting in aggressive tumors resistant to conventional treatments. At the heart of this therapeutic challenge are cancer stem cells (CSCs), which possess distinctive capabilities for self-renewal, differentiation, and generation of diverse tumor cell populations. These CSCs have been identified across multiple tissue types, including lung, colon, breast, pancreas, and ovary. Research has demonstrated that CSC subpopulations contribute significantly to therapeutic resistance, tumor recurrence, and metastasis by regulating multiple signaling pathways, making them compelling targets for cancer therapy. Notably, emerging evidence suggests that natural products may offer protective benefits against cancer development while potentially targeting CSCs. This review synthesizes current knowledge of CSCs, examining their identifying markers, isolation techniques, study methods, and associated signaling pathways. Additionally, we explore various natural products that specifically target CSCs across different cancer types, presenting potential strategies to address the persistent challenges of drug resistance and cancer relapse.

Keywords

Phytochemicals / stem cell markers / signaling pathways

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49.

[2] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73: 17-48.

[3] Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017; 23: 1124—34.

[4] Klonisch T, Wiechec E, Hombach—Klonisch S, Ande SR, Wesselborg S, Schulze—Osthoff K, et al. Cancer stem cell markers in common cancers — therapeutic implications. Trends Mol Med. 2008; 14: 450-60.

[5] Martin—Belmonte F, Perez—Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer. 2011; 12: 23-38.

[6] Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3: 730-7.

[7] Smalley M, Ashworth A. Stem cells and breast cancer: A field in transit. Nat Rev Cancer. 2003; 3: 832-44.

[8] Ricci—Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon—cancer—initiating cells. Nature. 2007; 445: 111—5.

[9] Kim CFB, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005; 121: 823—35.

[10] Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67: 1030—7.

[11] Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63: 5821—8.

[12] Ginestier C, Hur MH, Charafe—Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1: 555-67.

[13] Phi LTH, Sari IN, Yang Y, Lee S, Jun N, Kim KS, et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int. 2018; 2018: 5416923.

[14] Hausser J, Alon U. Tumour heterogeneity and the evolutionary trade—offs of cancer. Nat Rev Cancer. 2020; 20: 247-57.

[15] Sharifi—Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, et al. Paclitaxel: Application in Modern Oncology and Nanomedicine—Based Cancer Therapy. Oxid Med Cell Longev. 2021; 2021: 3687700.

[16] Zhou H, Zhang J, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther. 2021; 6: 62.

[17] Phillips TM, McBride WH, Pajonk F. The Response of CD24^−/low/CD44⁺ Breast Cancer—Initiating Cells to Radiation. J Natl Cancer Inst. 2006; 98: 1777—85.

[18] Nunes T, Hamdan D, Leboeuf C, Bouchtaoui ME, Gapihan G, Nguyen TT, et al. Targeting Cancer Stem Cells to Overcome Chemoresistance. Int J Mol Sci. 2018; 19: 4036.

[19] Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let—7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007; 131: 1109-23.

[20] Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006; 7: 988-94.

[21] Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444: 756-60.

[22] Khatoon E, Banik K, Harsha C, Sailo BL, Thakur KK, Khwairakpam AD, et al. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Semin Cancer Biol. 2022; 80: 306-39.

[23] Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova I. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018; 53: 156-67.

[24] Lee HE, Kim JH, Kim YJ, Choi SY, Kim S, Kang E, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011; 104: 1730—8.

[25] Radisky DC. Epithelial—mesenchymal transition. J Cell Sci. 2005; 118: 4325-6.

[26] Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019; 234: 8381-95.

[27] Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, et al. Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 2006; 66: 9339-44.

[28] Toledo—Guzmán ME, Bigoni—Ordóñez GD, Hernández MI, Ortiz—Sánchez E. Cancer stem cell impact on clinical oncology. World J Stem Cells. 2018; 10: 183-95.

[29] Zhao W, Li Y, Zhang X. Stemness—Related Markers in Cancer. Cancer Transl Med. 2017; 3: 87-95.

[30] Walcher L, Kistenmacher A, Suo H, Kitte R, Dluczek S, Strauß A, et al. Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol. 2020; 11: 1280.

[31] Gee K, Kryworuchko M, Kumar A. Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2004; 52: 13-26.

[32] Guo W, Frenette PS. Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Oncogene. 2014; 33: 537—8.

[33] Olsson E, Honeth G, Bendahl P, Saal LH, Gruvberger—Saal S, Ringnér M, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer. 2011; 11: 418.

[34] Martincuks A, Li P, Zhao Q, Zhang C, Li Y, Yu H, et al. CD44 in Ovarian Cancer Progression and Therapy Resistance—A Critical Role for STAT3. Front Oncol. 2020; 10: 589601.

[35] Si D, Yin F, Peng J, Zhang G. High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas. Cancer Manag Res. 2020; 12: 769—75.

[36] Hu Y, Zhang Y, Gao J, Lian X, Wang Y. The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta—analysis and TCGA data. Bioengineered. 2020; 11: 572-81.

[37] Kavitha L, Priyadharsini JV, Kattula D, Rao UKM, Srikanth RB, Kuzhalmozhi M, et al. Expression of CD44 in Head and Neck Squamous Cell Carcinoma—An In—Silico Study. Glob Med Genet. 2023; 10: 221—8.

[38] Zhao S, Chen C, Chang K, Karnad A, Jagirdar J, Kumar AP, et al. CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy. Clin Cancer Res. 2016; 22: 5592-604.

[39] Ji H, Kong L, Wang Y, Hou Z, Kong W, Qi J, et al. CD44 expression is correlated with osteosarcoma cell progression and immune infiltration and affects the Wnt/β—catenin signaling pathway. J Bone Oncol. 2023; 41: 100487.

[40] Cho Y, Lee H, Kang H, Kim H, Kim S, Chun K. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget. 2015; 6: 8709—21.

[41] Faassen AE, Schrager JA, Klein DJ, Oegema TR, Couchman JR, McCarthy JB. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen—mediated melanoma cell motility and invasion. J Cell Biol. 1992; 116: 521—31.

[42] Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor—ligand interaction between CD44 and osteopontin (Eta—1). Science. 1996; 271: 509—12.

[43] Knutson JR, Iida J, Fields GB, McCarthy JB. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell. 1996; 7: 383-96.

[44] Bourguignon LYW, Shiina M, Li J. Hyaluronan—CD44 Interaction Promotes Oncogenic Signaling, microRNA Functions, Chemoresistance, and Radiation Resistance in Cancer Stem Cells Leading to Tumor Progression. Adv Cancer Res. 2014; 123: 255-75.

[45] Zöller M. CD44: can a cancer—initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011; 11: 254-67.

[46] Screaton GR, Bell MV, Bell JI, Jackson DG. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp—1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem. 1993; 268: 12235—8.

[47] Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer. Cell Signal. 2014; 26: 2234—9.

[48] Burman DR, Das S, Das C, Bhattacharya R. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance. Mol Biol Rep. 2021; 48: 897-914.

[49] Wang SJ, Wreesmann VB, Bourguignon LYW. Association of CD44 V3—containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck. 2007; 29: 550—8.

[50] Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 2012; 3: 883.

[51] Shu X, Liu H, Pan Y, Sun L, Yu L, Sun L, et al. Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines. Mol Cell Biochem. 2019; 459: 35-47.

[52] Watanabe T, Okumura T, Hirano K, Yamaguchi T, Sekine S, Nagata T, et al. Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer. Oncol Lett. 2017; 13: 281—8.

[53] Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol. 2010; 7: 100—3.

[54] Aigner S, Ruppert M, Hubbe M, Sammar M, Sthoeger Z, Butcher EC, et al. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P—selectin. Int Immunol. 1995; 7: 1557-65.

[55] Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44⁺ CD24^— prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008; 98: 756-65.

[56] Mishra S, Tiwari V, Arora A, Gupta S, Anand N, Husain N. Increased Expression of Oct4, Nanog and CD24 Predicts Poor Response to Chemo—Radiotherapy and Unfavourable Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2020; 21: 2539—47.

[57] Sagiv E, Memeo L, Karin A, Kazanov D, Jacob—Hirsch J, Mansukhani M, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology. 2006; 131: 630—9.

[58] Kristiansen G, Winzer K, Mayordomo E, Bellach J, Schlüns K, Denkert C, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res. 2003; 9: 4906—13.

[59] Nakamura K, Terai Y, Tanabe A, Ono YJ, Hayashi M, Maeda K, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial—mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncol Rep. 2017; 37: 3189-200.

[60] Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer. 2003; 88: 231—6.

[61] Christian SL. CD24 as a Potential Therapeutic Target in Patients with B—Cell Leukemia and Lymphoma: Current Insights. Onco Targets Ther. 2022; 15: 1391—402.

[62] Sun J, Feng D, Xi H, Luo J, Zhou Z, Liu Q, et al. CD24 blunts the sensitivity of retinoblastoma to vincristine by modulating autophagy. Mol Oncol. 2020; 14: 1740-59.

[63] Pandey V, Jung Y, Kang J, Steiner M, Qian P, Banerjee A, et al. Artemin Reduces Sensitivity to Doxorubicin and Paclitaxel in Endometrial Carcinoma Cells through Specific Regulation of CD24. Transl Oncol. 2010; 3: 218—29.

[64] Soni P, Qayoom S, Husain N, Kumar P, Chandra A, Ojha BK, et al. CD24 and Nanog expression in Stem Cells in Glioblastoma: Correlation with Response to Chemoradiation and Overall Survival. Asian Pac J Cancer Prev. 2017; 18: 2215—9.

[65] Modur V, Joshi P, Nie D, Robbins KT, Khan AU, Rao K. CD24 Expression May Play a Role as a Predictive Indicator and a Modulator of Cisplatin Treatment Response in Head and Neck Squamous Cellular Carcinoma. PLoS One. 2016; 11: e0156651.

[66] Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec—10 is a target for cancer immunotherapy. Nature. 2019; 572: 392-6.

[67] Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, et al. Aldehyde Dehydrogenase 1 A1—Positive Cell Population Is Enriched in Tumor—Initiating Cells and Associated with Progression of Bladder Cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19: 327-37.

[68] Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int. 2012; 62: 112—9.

[69] Yang L, Ren Y, Yu X, Qian F, Bian B, Xiao H, et al. ALDH1A1 defines invasive cancer stem—like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol. 2014; 27: 775-83.

[70] Wang Y, Yo Y, Lee H, Liao Y, Chao T, Su P, et al. ALDH1—bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol. 2012; 180: 1159-69.

[71] Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, et al. Aldehyde dehydrogenase 1 is a tumor stem cell—associated marker in lung cancer. Mol Cancer Res. 2009; 7: 330-8.

[72] Chen Y, Chen Y, Hsu H, Tseng L, Huang P, Lu K, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009; 385: 307—13.

[73] Charafe—Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde Dehydrogenase 1—Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer. Clin Cancer Res. 2010; 16: 45-55.

[74] Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics. 2005; 2: 138-43.

[75] Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, et al. Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract. Mod Pathol. 2013; 26: 117-24.

[76] Duester G, Mic FA, Molotkov A. Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue—specific metabolism to retinoic acid. Chem Biol Interact. 2003; 143—144: 201-10.

[77] Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle. 2009; 8: 3297—302.

[78] Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide—resistant L1210 leukemia. Cancer Res. 1984; 44: 5156-60.

[79] Yoshida A, Davé V, Han H, Scanlon KJ. Enhanced transcription of the cytosolic ALDH gene in cyclophosphamide resistant human carcinoma cells. Adv Exp Med Biol. 1993; 328: 63-72.

[80] Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood. 1990; 75: 1947—50.

[81] Dimou A, Neumeister V, Agarwal S, Anagnostou V, Syrigos K, Rimm DL. Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non—small cell lung cancer. Am J Pathol. 2012; 181: 1436—42.

[82] Li Z. CD133: a stem cell biomarker and beyond. Exp Hematol Oncol. 2013; 2: 17.

[83] Kim W, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017; 50: 285-98.

[84] Handgretinger R, Gordon PR, Leimig T, Chen X, Buhring H, Niethammer D, et al. Biology and plasticity of CD133⁺ hematopoietic stem cells. Ann N Y Acad Sci. 2003; 996: 141-51.

[85] O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445: 106—10.

[86] Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1: 313-23.

[87] Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, et al. Expression of CD133—1 and CD133—2 in ovarian cancer. Int J Gynecol Cancer. 2008; 18: 506-14.

[88] Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Virgilio AD, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008; 15: 504-14.

[89] Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006; 351: 820-4.

[90] Vira D, Basak SK, Veena MS, Wang MB, Batra RK, Srivatsan ES. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 2012; 31: 733—51.

[91] Yiming L, Yunshan G, Bo M, Yu Z, Tao W, Gengfang L, et al. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta—analysis. Oncotarget. 2015; 6: 42019—27.

[92] Pampaloni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007; 8: 839—45.

[93] Patel N, Baranwal S, Patel BB. A Strategic Approach to Identification of Selective Inhibitors of Cancer Stem Cells. Methods Mol Biol. 2022; 2303: 765-77.

[94] Yang Y, Cui J, Kong Y, Hou Y, Ma C. Organoids: new frontiers in tumor immune microenvironment research. Front Immunol. 2024; 15: 1422031.

[95] Xin M, Li Q, Wang D, Wang Z. Organoids for Cancer Research: Advances and Challenges. Adv Biol (Weinh). 2024; 8: e2400056.

[96] Thorel L, Perréard M, Florent R, Divoux J, Coffy S, Vincent A, et al. Patient—derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024; 56: 1531—51.

[97] Balicki D. Moving Forward in Human Mammary Stem Cell Biology and Breast Cancer Prognostication Using ALDH1. Cell Stem Cell. 2007; 1: 485—7.

[98] Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009; 69: 3382—9.

[99] Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest. 2010; 90: 234-44.

[100] Thakur R, Trivedi R, Rastogi N, Singh M, Mishra DP. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep. 2015; 5: 10194.

[101] Chen N, Bezzina R, Hinch E, Lewandowski PA, Cameron—Smith D, Mathai ML, et al. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high—fat diet. Nutr Res. 2009; 29: 784-93.

[102] Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183: 1797-806.

[103] Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side—population phenotype. Nat Med. 2001; 7: 1028—34.

[104] Moserle L, Ghisi M, Amadori A, Indraccolo S. Side population and cancer stem cells: therapeutic implications. Cancer Lett. 2010; 288: 1-9.

[105] Jariyal H, Gupta C, Bhat VS, Wagh JR, Srivastava A. Advancements in Cancer Stem Cell Isolation and Characterization. Stem Cell Rev Rep. 2019; 15: 755-73.

[106] Dobbin ZC, Landen CN. Isolation and Characterization of Potential Cancer Stem Cells from Solid Human Tumors—Potential Applications. Curr Protoc Pharmacol. 2013; 63: 14.28.1-9.

[107] Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014; 346: 1248012.

[108] Espinoza I, Pochampally R, Xing F, Watabe K, Miele L. Notch signaling: targeting cancer stem cells and epithelial—to—mesenchymal transition. Onco Targets Ther. 2013; 6: 1249-59.

[109] Fisher ML, Kerr C, Adhikary G, Grun D, Xu W, Keillor JW, et al. Transglutaminase Interaction with α6/β4—Integrin Stimulates YAP1—Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation. Cancer Res. 2016; 76: 7265-76.

[110] Justilien V, Fields AP. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin Cancer Res. 2015; 21: 505—13.

[111] Xia P, Xu X. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015; 5: 1602-9.

[112] Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, et al. JAK—STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem—like cells. Cancer Res. 2013; 73: 5288-98.

[113] Amiri KI, Richmond A. Role of nuclear factor—κ B in melanoma. Cancer Metastasis Rev. 2005; 24: 301-13.

[114] Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015; 12: 445-64.

[115] Nusse R, Fuerer C, Ching W, Harnish K, Logan C, Zeng A, et al. Wnt signaling and stem cell control. Cold Spring Harb Symp Quant Biol. 2008; 73: 59-66.

[116] Katoh M. Canonical and non—canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017; 51: 1357—69.

[117] Na H, Shin W, Ludwig A, Lee S. The cytosolic domain of protein—tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and γ—secretase, enhances cell proliferation and migration in colon cancer cells. J Biol Chem. 2012; 287: 25001—9.

[118] Chae W, Bothwell ALM. Canonical and Non—Canonical Wnt Signaling in Immune Cells. Trends Immunol. 2018; 39: 830-47.

[119] Park S, Kim J, Jang G, Choi J, Kim J, Lee C, et al. Aberrant activation of the CD45—Wnt signaling axis promotes stemness and therapy resistance in colorectal cancer cells. Theranostics. 2021; 11: 8755-70.

[120] Jang G, Kim J, Cho S, Park K, Jung J, Lee H, et al. Blockade of Wnt/β—catenin signaling suppresses breast cancer metastasis by inhibiting CSC—like phenotype. Sci Rep. 2015; 5: 12465.

[121] Hou P, Ma X, Zhang Q, Wu C, Liao W, Li J, et al. USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation. Genes Dev. 2019; 33: 1361—6.

[122] Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434: 843—50.

[123] Moreno—Londoño AP, Castañeda—Patlán MC, Sarabia—Sánchez MA, Macías—Silva M, Robles—Flores M. Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids. Int J Mol Sci. 2023; 24: 5252.

[124] Barker N, Ridgway RA, Es JHv, Wetering Mvd, Begthel H, Born Mvd, et al. Crypt stem cells as the cells—of—origin of intestinal cancer. Nature. 2009; 457: 608—11.

[125] Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of β—Catenin—Tcf Signaling in Colon Cancer by Mutations in β—Catenin or APC. Science. 1997; 275: 1787—90.

[126] Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, et al. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019; 58: 1770—82.

[127] Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002; 1: 279-88.

[128] Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, et al. Expression of Wnt—5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 2006; 66: 10439—48.

[129] Kirstetter P, Anderson K, Porse BT, Jacobsen SEW, Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol. 2006; 7: 1048-56.

[130] Aster JC, Pear WS, Blacklow SC. The Varied Roles of Notch in Cancer. Annu Rev Pathol. 2017; 12: 245-75.

[131] Li L, Tang P, Li S, Qin X, Yang H, Wu C, et al. Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy. Med Oncol. 2017; 34: 180.

[132] Siebel C, Lendahl U. Notch Signaling in Development, Tissue Homeostasis, and Disease. Physiol Rev. 2017; 97: 1235-94.

[133] Ayaz F, Osborne BA. Non—canonical notch signaling in cancer and immunity. Front Oncol. 2014; 4: 345.

[134] Xiao W, Gao Z, Duan Y, Yuan W, Ke Y. Notch signaling plays a crucial role in cancer stem—like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma. J Exp Clin Cancer Res. 2017; 36: 41.

[135] Mangolini M, Maiques—Diaz A, Charalampopoulou S, Gerhard—Hartmann E, Bloehdorn J, Moore A, et al. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH—mediated immune escape. Nat Commun. 2022; 13: 6220.

[136] Xie M, He C, Wei S, Zhang L. Notch—1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non—small cell lung cancer in vitro and in vivo. Eur J Cancer. 2013; 49: 3559-72.

[137] Li G, Zhou Z, Zhou H, Zhao L, Chen D, Chen H, et al. The expression profile and clinicopathological significance of Notch1 in patients with colorectal cancer: a meta—analysis. Future Oncol. 2017; 13: 2103—18.

[138] Maraver A, Fernández—Marcos PJ, Herranz D, Muñoz—Martin M, Gomez—Lopez G, Cañamero M, et al. Therapeutic effect of γ—secretase inhibition in Kras^G12V—driven non—small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell. 2012; 22: 222—34.

[139] Al—Kadash A, Alshaer W, Mahmoud IS, Wehaibi S, Zihlif M. Enhancing chemosensitivity of PANC1 pancreatic cancer cells to gemcitabine using ANGTPL4, Notch1 and NF—κβ1 siRNAs. Future Sci OA. 2024; 10: FSO918.

[140] Lu Y, Zhu Y, Deng S, Chen Y, Li W, Sun J, et al. Targeting the Sonic Hedgehog Pathway to Suppress the Expression of the Cancer Stem Cell (CSC)—Related Transcription Factors and CSC—Driven Thyroid Tumor Growth. Cancers (Basel). 2021; 13: 418.

[141] Merchant AA, Matsui W. Targeting Hedgehog — a Cancer Stem Cell Pathway. Clin Cancer Res. 2010; 16: 3130-40.

[142] Pietrobono S, Gagliardi S, Stecca B. Non—canonical Hedgehog Signaling Pathway in Cancer: Activation of GLI Transcription Factors Beyond Smoothened. Front Genet. 2019; 10: 556.

[143] Polizio AH, Chinchilla P, Chen X, Kim S, Manning DR, Riobo NA. Heterotrimeric Gi proteins link Hedgehog signaling to activation of Rho small GTPases to promote fibroblast migration. J Biol Chem. 2011; 286: 19589—96.

[144] Varnat F, Siegl—Cachedenier I, Malerba M, Gervaz P, Altaba ARi. Loss of WNT—TCF addiction and enhancement of HH—GLI1 signalling define the metastatic transition of human colon carcinomas. EMBO Mol Med. 2010; 2: 440-57.

[145] Po A, Silvano M, Miele E, Capalbo C, Eramo A, Salvati V, et al. Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma. Oncogene. 2017; 36: 4641—52.

[146] Eberl M, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K, et al. Hedgehog—EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour—initiating pancreatic cancer cells. EMBO Mol Med. 2012; 4: 218-33.

[147] Reyniès Ad, Javelaud D, Elarouci N, Marsaud V, Gilbert C, Mauviel A. Large—scale pan—cancer analysis reveals broad prognostic association between TGF—β ligands, not Hedgehog, and GLI1/2 expression in tumors. Sci Rep. 2020; 10: 14491.

[148] Riaz SK, Ke Y, Wang F, Kayani MA, Malik MFA. Influence of SHH/GLI1 axis on EMT mediated migration and invasion of breast cancer cells. Sci Rep. 2019; 9: 6620.

[149] Song X, Yan L, Lu C, Zhang C, Zhu F, Yang J, et al. Activation of hedgehog signaling and its association with cisplatin resistance in ovarian epithelial tumors. Oncol Lett. 2018; 15: 5569—76.

[150] Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 2014; 25: 139-51.

[151] Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, et al. Cyclopamine—mediated hedgehog pathway inhibition depletes stem—like cancer cells in glioblastoma. Stem Cells. 2007; 25: 2524-33.

[152] Wang F, Ma L, Zhang Z, Liu X, Gao H, Zhuang Y, et al. Hedgehog Signaling Regulates Epithelial—Mesenchymal Transition in Pancreatic Cancer Stem—Like Cells. J Cancer. 2016; 7: 408-17.

[153] Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, et al. Human colon cancer epithelial cells harbour active HEDGEHOG—GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med. 2009; 1: 338-51.

[154] Bai D, Ueno L, Vogt PK. Akt—mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt. Int J Cancer. 2009; 125: 2863-70.

[155] Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014; 4: 64.

[156] Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF—κB by the Akt/PKB kinase. Curr Biol. 1999; 9: 601—4.

[157] Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019; 18: 26.

[158] Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, et al. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol. 2014; 45: 567-74.

[159] Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, et al. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Transl Oncol. 2013; 6: 649—59.

[160] Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. Acquisition of epithelial—mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013; 4: e875.

[161] Huang F, Wu D, Zhang L, Yu Y, Yuan X, Li W, et al. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett. 2013; 336: 96-105.

[162] Jung M, Rho J, Kim Y, Jung JE, Jin YB, Ko Y, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug—resistant non—small cell lung cancer cells. Oncogene. 2013; 32: 209-21.

[163] Blasio AD, Fiore RD, Pratelli G, Drago—Ferrante R, Saliba C, Baldacchino S, et al. A loop involving NRF2, miR—29b—1—5p and AKT, regulates cell fate of MDA—MB—231 triple—negative breast cancer cells. J Cell Physiol. 2020; 235: 629—37.

[164] Chen Y, Su C, Deng W, Lock LF, Donovan PJ, Kayala MA, et al. Mitochondrial Akt Signaling Modulated Reprogramming of Somatic Cells. Sci Rep. 2019; 9: 9919.

[165] Dong X, Yang Y, Zhou Y, Bi X, Zhao N, Zhang Z, et al. Glutathione S—transferases P1 protects breast cancer cell from adriamycin—induced cell death through promoting autophagy. Cell Death Differ. 2019; 26: 2086—99.

[166] Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14: 736—46.

[167] Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015; 113: 365—71.

[168] Dutta P, Sabri N, Li J, Li WX. Role of STAT3 in lung cancer. JAKSTAT. 2015; 3: e999503.

[169] Choi SI, Kim SY, Lee JH, Kim JY, Cho EW, Kim I. Osteopontin production by TM4SF4 signaling drives a positive feedback autocrine loop with the STAT3 pathway to maintain cancer stem cell—like properties in lung cancer cells. Oncotarget. 2017; 8: 101284-97.

[170] Li A, Bai X, Li N, Cai S, Banerjee A, Lavudi K, et al. Cancer stem cells maintain stemness via autocrine activation of the IFN/JAK/STAT signaling pathway. Cancer Res. 2023; 83: 2428.

[171] Hu C, Li M, Guo T, Wang S, Huang W, Yang K, et al. Anti—metastasis activity of curcumin against breast cancer via the inhibition of stem cell—like properties and EMT. Phytomedicine. 2019; 58: 152740.

[172] Vikram P, Chiruvella KK, Ripain IHA, Arifullah M. A recent review on phytochemical constituents and medicinal properties of kesum (Polygonum minus Huds.) . Asian Pac J Trop Biomed. 2014; 4: 430-5.

[173] Taylor WF, Jabbarzadeh E. The use of natural products to target cancer stem cells. Am J Cancer Res. 2017; 7: 1588-605.

[174] Mukherjee S, Mazumdar M, Chakraborty S, Manna A, Saha S, Khan P, et al. Curcumin inhibits breast cancer stem cell migration by amplifying the E—cadherin/β—catenin negative feedback loop. Stem Cell Res Ther. 2014; 5: 116.

[175] Stratton CF, Newman DJ, Tan DS. Cheminformatic comparison of approved drugs from natural product versus synthetic origins. Bioorg Med Chem Lett. 2015; 25: 4802—7.

[176] Harvey AL, Edrada—Ebel R, Quinn RJ. The re—emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015; 14: 111-29.

[177] Atanasov AG, Waltenberger B, Pferschy—Wenzig E, Linder T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant—derived natural products: A review. Biotechnol Adv. 2015; 33: 1582-614.

[178] Waltenberger B, Mocan A, Šmejkal K, Heiss EH, Atanasov AG. Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders. Molecules. 2016; 21: 807.

[179] Key TJ. Fruit and vegetables and cancer risk. Br J Cancer. 2011; 104: 6-11.

[180] Thomas R, Butler E, Macchi F, Williams M. Phytochemicals in cancer prevention and management. BJMP. 2015; 8: a815.

[181] Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020; 83: 770-803.

[182] Oh J, Hlatky L, Jeong Y, Kim D. Therapeutic Effectiveness of Anticancer Phytochemicals on Cancer Stem Cells. Toxins (Basel). 2016; 8: 199.

[183] Chan MM, Chen R, Fong D. Targeting cancer stem cells with dietary phytochemical — Repositioned drug combinations. Cancer Lett. 2018; 433: 53-64.

[184] Huang B, Zhang Y. Teaching an old dog new tricks: Drug discovery by repositioning natural products and their derivatives. Drug Discov Today. 2022; 27: 1936—44.

[185] Dey P, Kundu A, Kumar A, Gupta M, Lee BM, Bhakta T, et al. Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids). In: Sanches Silva A, Nabavi SF, Saeedi M, Nabavi SM, editors. Recent Advances in Natural Products Analysis. Boston: Elsevier; 2020. pp. 505-67.

[186] Talib WH, Daoud S, Mahmod AI, Hamed RA, Awajan D, Abuarab SF, et al. Plants as a Source of Anticancer Agents: From Bench to Bedside. Molecules. 2022; 27: 4818.

[187] Saklani A, Kutty SK. Plant—derived compounds in clinical trials. Drug Discov Today. 2008; 13: 161-71.

[188] Monisha J, Jaiswal A, Banik K, Choudhary H, Singh AK, Bordoloi D, et al. Cancer Cell Chemoresistance: A Prime Obstacle in Cancer Therapy. In: Cancer Cell Chemoresistance and Chemosensitization. WORLD SCIENTIFIC; 2018. pp. 15-49.

[189] Weng C, Yen G. Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev. 2012; 38: 76-87.

[190] Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014; 19: 20091—112.

[191] Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res. 2002; 22: 4179—81.

[192] Lestari MLAD, Indrayanto G. Curcumin. Profiles Drug Subst Excip Relat Methodol. 2014; 39: 113-204.

[193] Wright LE, Frye JB, Gorti B, Timmermann BN, Funk JL. Bioactivity of turmeric—derived curcuminoids and related metabolites in breast cancer. Curr Pharm Des. 2013; 19: 6218—25.

[194] Vera—Ramirez L, Pérez—Lopez P, Varela—Lopez A, Ramirez—Tortosa M, Battino M, Quiles JL. Curcumin and liver disease. Biofactors. 2013; 39: 88-100.

[195] Subramaniam D, Ramalingam S, Linehan DC, Dieckgraefe BK, Postier RG, Houchen CW, et al. RNA binding protein CUGBP2/CELF2 mediates curcumin—induced mitotic catastrophe of pancreatic cancer cells. PLoS One. 2011; 6: e16958.

[196] Sha J, Li J, Wang W, Pan L, Cheng J, Li L, et al. Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU—145 cells by down regulating Notch signaling. Biomed Pharmacother. 2016; 84: 177-84.

[197] Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down—regulation of STAT3—NFκB signaling. Anticancer Res. 2015; 35: 39-46.

[198] Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat. 2010; 122: 777-85.

[199] Charpentier MS, Whipple RA, Vitolo MI, Boggs AE, Slovic J, Thompson KN, et al. Curcumin Targets Breast Cancer Stem—like Cells with Microtentacles That Persist in Mammospheres and Promote Reattachment. Cancer Res. 2014; 74: 1250-60.

[200] Gersey ZC, Rodriguez GA, Barbarite E, Sanchez A, Walters WM, Ohaeto KC, et al. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer. 2017; 17: 99.

[201] Almanaa TN, Geusz ME, Jamasbi RJ. Effects of curcumin on stem—like cells in human esophageal squamous carcinoma cell lines. BMC Complement Altern Med. 2012; 12: 195.

[202] Ryu M, Cho M, Song J, Yun Y, Choi I, Kim D, et al. Natural derivatives of curcumin attenuate the Wnt/β—catenin pathway through down—regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun. 2008; 377: 1304—8.

[203] Zhou Q, Ye M, Lu Y, Zhang H, Chen Q, Huang S, et al. Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell—Like Breast Cancer Cells. PLoS One. 2015; 10: e0136694.

[204] Wen C, Fu L, Huang J, Dai Y, Wang B, Xu G, et al. Curcumin reverses doxorubicin resistance via inhibition the efflux function of ABCB4 in doxorubicinresistant breast cancer cells. Mol Med Rep. 2019; 19: 5162—8.

[205] Wang L, Hu R, Dai A. Curcumin Increased the Sensitivity of Non—Small—Cell Lung Cancer to Cisplatin through the Endoplasmic Reticulum Stress Pathway. Evid Based Complement Alternat Med. 2022; 2022: 6886366.

[206] James MI, Iwuji C, Irving G, Karmokar A, Higgins JA, Griffin—Teal N, et al. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett. 2015; 364: 135—41.

[207] Kuttan R, Sudheeran PC, Josph CD. Turmeric and curcumin as topical agents in cancer therapy. Tumori. 1987; 73: 29-31.

[208] Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001; 7: 1894-900.

[209] Howells LM, Iwuji COO, Irving GRB, Barber S, Walter H, Sidat Z, et al. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. J Nutr. 2019; 149: 1133—9.

[210] Mahammedi H, Planchat E, Pouget M, Durando X, Curé H, Guy L, et al. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration—Resistant Prostate Cancer: A Pilot Phase II Study. Oncology. 2016; 90: 69-78.

[211] Ghalaut VS, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J Oncol Pharm Pract. 2012; 18: 186-90.

[212] Lançon A, Hanet N, Jannin B, Delmas D, Heydel J, Lizard G, et al. Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos. 2007; 35: 699-703.

[213] Coutinho DdS, Pacheco MT, Frozza RL, Bernardi A. Anti—Inflammatory Effects of Resveratrol: Mechanistic Insights. Int J Mol Sci. 2018; 19: 1812.

[214] Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti—cancer agent: A review. Crit Rev Food Sci Nutr. 2018; 58: 1428—47.

[215] Sinha D, Biswas J, Sung B, Aggarwal BB, Bishayee A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets. 2012; 13: 1799-819.

[216] de la Lastra CA, Villegas I. Resveratrol as an anti—inflammatory and anti—aging agent: Mechanisms and clinical implications. Mol Nutr Food Res. 2005; 49: 405—30.

[217] Buhrmann C, Shayan P, Kraehe P, Popper B, Goel A, Shakibaei M. Resveratrol induces chemosensitization to 5—fluorouracil through up—regulation of intercellular junctions, Epithelial—to—mesenchymal transition and apoptosis in colorectal cancer. Biochem Pharmacol. 2015; 98: 51-68.

[218] Li W, Cao L, Chen X, Lei J, Ma Q. Resveratrol inhibits hypoxia—driven ROS—induced invasive and migratory ability of pancreatic cancer cells via suppression of the Hedgehog signaling pathway. Oncol Rep. 2016; 35: 1718-26.

[219] Tang X, Shi L, Xie N, Liu Z, Qian M, Meng F, et al. SIRT7 antagonizes TGF—β signaling and inhibits breast cancer metastasis. Nat Commun. 2017; 8: 318.

[220] Fu Y, Chang H, Peng X, Bai Q, Yi L, Zhou Y, et al. Resveratrol inhibits breast cancer stem—like cells and induces autophagy via suppressing Wnt/β—catenin signaling pathway. PLoS One. 2014; 9: e102535.

[221] Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, et al. Resveratrol suppresses growth of cancer stem—like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat. 2011; 130: 387-98.

[222] Reddivari L, Charepalli V, Radhakrishnan S, Vadde R, Elias RJ, Lambert JD, et al. Grape compounds suppress colon cancer stem cells in vitro and in a rodent model of colon carcinogenesis. BMC Complement Altern Med. 2016; 16: 278.

[223] Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, et al. Phase I Randomized, Double—Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and Pharmacodynamics. Cancer Prev Res (Phila). 2011; 4: 1419-25.

[224] Clark PA, Bhattacharya S, Elmayan A, Darjatmoko SR, Thuro BA, Yan MB, et al. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem—like cells to suppress growth and infiltration. J Neurosurg. 2017; 126: 1448-60.

[225] Cilibrasi C, Riva G, Romano G, Cadamuro M, Bazzoni R, Butta V, et al. Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway. PLoS One. 2017; 12: e0169854.

[226] Shankar S, Nall D, Tang S, Meeker D, Passarini J, Sharma J, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and Kras^G12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial—mesenchymal transition. PLoS One. 2011; 6: e16530.

[227] Zhou C, Qian W, Ma J, Cheng L, Jiang Z, Yan B, et al. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Cell Prolif. 2019; 52: e12514.

[228] Shen Y, Lin C, Chi W, Wang C, Hsieh Y, Wei Y, et al. Resveratrol Impedes the Stemness, Epithelial—Mesenchymal Transition, and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation. Evid Based Complement Alternat Med. 2013; 2013: 590393.

[229] Chen A, Zhang L. The Antioxidant (—)—Epigallocatechin—3—gallate Inhibits Rat Hepatic Stellate Cell Proliferation in Vitro by Blocking the Tyrosine Phosphorylation and Reducing the Gene Expression of Platelet—derived Growth Factor—β Receptor. J Biol Chem. 2003; 278: 23381—9.

[230] Kim H, Quon MJ, Kim J. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3—gallate. Redox Biol. 2014; 2: 187-95.

[231] Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009; 2: 270—8.

[232] Lee M, Kim C, Kim Y. Green Tea (—)—Epigallocatechin—3—Gallate Reduces Body Weight with Regulation of Multiple Genes Expression in Adipose Tissue of Diet—Induced Obese Mice. Ann Nutr Metab. 2009; 54: 151-7.

[233] Liu X, Zhao K, Jing N, Zhao Y, Yang X. EGCG regulates fatty acid metabolism of high—fat diet—fed mice in association with enrichment of gut Akkermansia muciniphila. J Funct Foods. 2020; 75: 104261.

[234] Chen Y, Wang X, Zhang Q, Zhu J, Li Y, Xie C, et al. (?)—Epigallocatechin—3—Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/?—Catenin Pathway. Nutrients. 2017; 9: 572.

[235] Toden S, Tran H, Tovar—Camargo OA, Okugawa Y, Goel A. Epigallocatechin—3—gallate targets cancer stem—like cells and enhances 5—fluorouracil chemosensitivity in colorectal cancer. Oncotarget. 2016; 7: 16158—71.

[236] Zhu J, Jiang Y, Yang X, Wang S, Xie C, Li X, et al. Wnt/β—catenin pathway mediates (−)—Epigallocatechin—3—gallate (EGCG) inhibition of lung cancer stem cells. Biochem Biophys Res Commun. 2017; 482: 15-21.

[237] Das A, Haque I, Ray P, Ghosh A, Dutta D, Quadir M, et al. CCN5 activation by free or encapsulated EGCG is required to render triple—negative breast cancer cell viability and tumor progression. Pharmacol Res Perspect. 2021; 9: e00753.

[238] Lee SH, Nam HJ, Kang HJ, Kwon HW, Lim YC. Epigallocatechin—3—gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur J Cancer. 2013; 49: 3210—8.

[239] Torres SR, Gresseau L, Benhamida M, Fernandez—Marrero Y, Annabi B. Epigallocatechin—3—Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling. Biomedicines. 2023; 11: 1000.

[240] Zhao H, Zhu W, Xie P, Li H, Zhang X, Sun X, et al. A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin—3—gallate protection in patients with locally advanced stage III non—small—cell lung cancer. Radiother Oncol. 2014; 110: 132-6.

[241] Trudel D, Labbé DP, Araya—Farias M, Doyen A, Bazinet L, Duchesne T, et al. A two—stage, single—arm, phase II study of EGCG—enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol. 2013; 131: 357-61.

[242] Hertog MG. Epidemiological evidence on potential health properties of flavonoids. Proc Nutr Soc. 1996; 55: 385-97.

[243] Atrahimovich D, Vaya J, Khatib S. The effects and mechanism of flavonoid—rePON1 interactions. Structure—activity relationship study. Bioorg Med Chem. 2013; 21: 3348-55.

[244] Pietta PG. Flavonoids as antioxidants. J Nat Prod. 2000; 63: 1035—42.

[245] Friedman M. Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. Mol Nutr Food Res. 2007; 51: 116-34.

[246] Al—Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, Al—Mssallem MQ. Flavonoids as Potential Anti—Inflammatory Molecules: A Review. Molecules. 2022; 27: 2901.

[247] Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res. 2008; 52: 507—26.

[248] Dębińska A, Sozańska B. Dietary Polyphenols—Natural Bioactive Compounds with Potential for Preventing and Treating Some Allergic Conditions. Nutrients. 2023; 15: 4823.

[249] David AVA, Arulmoli R, Parasuraman S. Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid. Pharmacogn Rev. 2016; 10: 84-9.

[250] Srivastava S, Somasagara RR, Hegde M, Nishana M, Tadi SK, Srivastava M, et al. Quercetin, a Natural Flavonoid Interacts with DNA, Arrests Cell Cycle and Causes Tumor Regression by Activating Mitochondrial Pathway of Apoptosis. Sci Rep. 2016; 6: 24049.

[251] Brisdelli F, Coccia C, Cinque B, Cifone MG, Bozzi A. Induction of apoptosis by quercetin: different response of human chronic myeloid (K562) and acute lymphoblastic (HSB—2) leukemia cells. Mol Cell Biochem. 2007; 296: 137-49.

[252] Ranganathan S, Halagowder D, Sivasithambaram ND. Quercetin Suppresses Twist to Induce Apoptosis in MCF—7 Breast Cancer Cells. PLoS One. 2015; 10: e0141370.

[253] Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. Altern Med Rev. 2000; 5: 196-208.

[254] Priyadarsini RV, Murugan RS, Maitreyi S, Ramalingam K, Karunagaran D, Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria—mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF—κB inhibition. Eur J Pharmacol. 2010; 649: 84-91.

[255] Dandawate PR, Subramaniam D, Jensen RA, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. Semin Cancer Biol. 2016; 40—41: 192-208.

[256] Yoshida M, Yamamoto M, Nikaido T. Quercetin arrests human leukemic T—cells in late G1 phase of the cell cycle. Cancer Res. 1992; 52: 6676-81.

[257] Choi JA, Kim JY, Lee JY, Kang CM, Kwon HJ, Yoo YD, et al. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int J Oncol. 2001; 19: 837-44.

[258] Richter M, Ebermann R, Marian B. Quercetin—induced apoptosis in colorectal tumor cells: possible role of EGF receptor signaling. Nutr Cancer. 1999; 34: 88-99.

[259] Erdogan S, Turkekul K, Dibirdik I, Doganlar O, Doganlar ZB, Bilir A, et al. Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway. Biomed Pharmacother. 2018; 107: 793-805.

[260] Tsai P, Cheng C, Lin C, Huang Y, Lee L, Kandaswami CC, et al. Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells. Anticancer Res. 2016; 36: 6367—80.

[261] Li S, Zhao Q, Wang B, Yuan S, Wang X, Li K. Quercetin reversed MDR in breast cancer cells through down—regulating P—gp expression and eliminating cancer stem cells mediated by YB—1 nuclear translocation. Phytother Res. 2018; 32: 1530—6.

[262] Shen X, Si Y, Wang Z, Wang J, Guo Y, Zhang X. Quercetin inhibits the growth of human gastric cancer stem cells by inducing mitochondrial—dependent apoptosis through the inhibition of PI3K/Akt signaling. Int J Mol Med. 2016; 38: 619—26.

[263] Chang W, Hu F, Yu C, Wang H, Feng H, Lan C, et al. Quercetin in elimination of tumor initiating stem—like and mesenchymal transformation property in head and neck cancer. Head Neck. 2013; 35: 413—9.

[264] Mertens—Talcott SU, Percival SS. Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett. 2005; 218: 141—51.

[265] Mouria M, Gukovskaya AS, Jung Y, Buechler P, Hines OJ, Reber HA, et al. Food—derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer. 2002; 98: 761-9.

[266] Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010; 37: 551-61.

[267] Egert S, Bosy—Westphal A, Seiberl J, Kürbitz C, Settler U, Plachta—Danielzik S, et al. Quercetin reduces systolic blood pressure and plasma oxidised low—density lipoprotein concentrations in overweight subjects with a high—cardiovascular disease risk phenotype: a double—blinded, placebo—controlled cross—over study. Br J Nutr. 2009; 102: 1065-74.

[268] Hostetler GL, Ralston RA, Schwartz SJ. Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity. Adv Nutr. 2017; 8: 423-35.

[269] Kim B, Jung N, Lee S, Sohng JK, Jung HJ. Apigenin Inhibits Cancer Stem Cell—Like Phenotypes in Human Glioblastoma Cells via Suppression of c—Met Signaling. Phytother Res. 2016; 30: 1833—40.

[270] Li Y, Xu J, Zhu G, Huang Z, Lu Y, Li X, et al. Apigenin suppresses the stem cell—like properties of triple—negative breast cancer cells by inhibiting YAP/TAZ activity. Cell Death Discov. 2018; 4: 105.

[271] Erdogan S, Turkekul K, Serttas R, Erdogan Z. The natural flavonoid apigenin sensitizes human CD44⁺ prostate cancer stem cells to cisplatin therapy. Biomed Pharmacother. 2017; 88: 210—7.

[272] Erdogan S, Doganlar O, Doganlar ZB, Serttas R, Turkekul K, Dibirdik I, et al. The flavonoid apigenin reduces prostate cancer CD44⁺ stem cell survival and migration through PI3K/Akt/NF—κB signaling. Life Sci. 2016; 162: 77-86.

[273] Ketkaew Y, Osathanon T, Pavasant P, Sooampon S. Apigenin inhibited hypoxia induced stem cell marker expression in a head and neck squamous cell carcinoma cell line. Arch Oral Biol. 2017; 74: 69-74.

[274] Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry. 2000; 55: 481-504.

[275] Chen C, Peng W, Tsai K, Hsu S. Luteolin suppresses inflammation—associated gene expression by blocking NF—κB and AP—1 activation pathway in mouse alveolar macrophages. Life Sci. 2007; 81: 1602-14.

[276] Chung JG, Hsia TC, Kuo HM, Li YC, Lee YM, Lin SS, et al. Inhibitory actions of luteolin on the growth and arylamine N—acetyltransferase activity in strains of Helicobacter pylori from ulcer patients. Toxicol In Vitro. 2001; 15: 191—8.

[277] Lien EJ, Ren S, Bui HH, Wang R. Quantitative structure—activity relationship analysis of phenolic antioxidants. Free Radic Biol Med. 1999; 26: 285-94.

[278] Neuhouser ML. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer. 2004; 50: 1-7.

[279] Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther. 2001; 90: 157-77.

[280] Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab. 2008; 93: 3295—8.

[281] Axlund SD, Sartorius CA. Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol. 2012; 357: 71-9.

[282] Cook MT, Liang Y, Besch—Williford C, Goyette S, Mafuvadze B, Hyder SM. Luteolin inhibits progestin—dependent angiogenesis, stem cell—like characteristics, and growth of human breast cancer xenografts. Springerplus. 2015; 4: 444.

[283] Zhao J, Li L, Wang Z, Li L, He M, Han S, et al. Luteolin attenuates cancer cell stemness in PTX—resistant oesophageal cancer cells through mediating SOX2 protein stability. Pharmacol Res. 2021; 174: 105939.

[284] Fahey JW, Wehage SL, Holtzclaw WD, Kensler TW, Egner PA, Shapiro TA, et al. Protection of humans by plant glucosinolates: efficiency of conversion of glucosinolates to isothiocyanates by the gastrointestinal microflora. Cancer Prev Res (Phila). 2012; 5: 603—11.

[285] Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. 2007; 55: 224-36.

[286] Tang L, Zirpoli GR, Guru K, Moysich KB, Zhang Y, Ambrosone CB, et al. Intake of cruciferous vegetables modifies bladder cancer survival. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1806—11.

[287] Chen Y, Li Y, Wang X, Meng Y, Zhang Q, Zhu J, et al. Phenethyl isothiocyanate inhibits colorectal cancer stem cells by suppressing Wnt/β—catenin pathway. Phytother Res. 2018; 32: 2447—55.

[288] Shin JM, Lim E, Cho YS, Nho CW. Cancer—preventive effect of phenethyl isothiocyanate through tumor microenvironment regulation in a colorectal cancer stem cell xenograft model. Phytomedicine. 2021; 84: 153493.

[289] Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, et al. Phenethyl isothiocyanate hampers growth and progression of HER2—positive breast and ovarian carcinoma by targeting their stem cell compartment. Cell Oncol (Dordr). 2019; 42: 815-28.

[290] Zhang T, Zhang W, Hao M. Phenethyl isothiocyanate reduces breast cancer stem cell—like properties by epigenetic reactivation of CDH1. Oncol Rep. 2021; 45: 337-48.

[291] Nguyen YT, Moon JY, Ediriweera MK, Cho SK. Phenethyl Isothiocyanate Suppresses Stemness in the Chemo— and Radio—Resistant Triple—Negative Breast Cancer Cell Line MDA—MB—231/IR Via Downregulation of Metadherin. Cancers (Basel). 2020; 12: 268.

[292] Yun JH, Kim K, Yoo G, Kim SY, Shin JM, Kim JH, et al. Phenethyl isothiocyanate suppresses cancer stem cell properties in vitro and in a xenograft model. Phytomedicine. 2017; 30: 42-9.

[293] Mahapatra E, Sengupta D, Kumar R, Dehury B, Das S, Roy M, et al. Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer. Front Pharmacol. 2022; 13: 803114.

[294] Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020; 10: 8721—43.

[295] Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105—11.

[296] Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, Yang CS. Hepatotoxicity of high oral dose (−)—epigallocatechin—3—gallate in mice. Food Chem Toxicol. 2010; 48: 409—16.

[297] Lu NT, Crespi CM, Liu NM, Vu JQ, Ahmadieh Y, Wu S, et al. A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. Phytother Res. 2016; 30: 160—8.

[298] Morrison KC, Hergenrother PJ. Natural products as starting points for the synthesis of complex and diverse compounds. Nat Prod Rep. 2014; 31: 6-14.

[299] Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007; 4: 807—18.

[300] Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011; 1215: 9-15.

[301] Mukherjee PK, Harwansh RK, Bhattacharyya S. Chapter 10 — Bioavailability of Herbal Products: Approach Toward Improved Pharmacokinetics. In: Mukherjee PK, editor. Evidence—Based Validation of Herbal Medicine. Boston: Elsevier; 2015. pp. 217-45.

[302] Ernest U, Chen H, Xu M, Taghipour YD, Asad MHHB, Rahimi R, et al. Anti—Cancerous Potential of Polyphenol—Loaded Polymeric Nanotherapeutics. Molecules. 2018; 23: 2787.

[303] Li C, Zhang J, Zu Y, Nie S, Cao J, Wang Q, et al. Biocompatible and biodegradable nanoparticles for enhancement of anti—cancer activities of phytochemicals. Chin J Nat Med. 2015; 13: 641—52.

[304] Hashem S, Ali TA, Akhtar S, Nisar S, Sageena G, Ali S, et al. Targeting cancer signaling pathways by natural products: Exploring promising anti—cancer agents. Biomed Pharmacother. 2022; 150: 113054.

[305] Sawadogo WR, Boly R, Cerella C, Teiten MH, Dicato M, Diederich M. A Survey of Marine Natural Compounds and Their Derivatives with Anti—cancer Activity Reported in 2012. Molecules. 2015; 20: 7097-142.

[306] Filippis BD, Ammazzalorso A, Fantacuzzi M, Giampietro L, Maccallini C, Amoroso R. Anticancer Activity of Stilbene—Based Derivatives. ChemMedChem. 2017; 12: 558-70.

[307] Ózsvári B, Magalhães LG, Latimer J, Kangasmetsa J, Sotgia F, Lisanti MP. A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity. Front Oncol. 2020; 10: 1528.